PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146
A Phase II Study of Oral Enzastaurin in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane-Containing Regimen
A Phase I/II Study of PTK787 in Combination with Trastuzumab in Patients with Newly Diagnosed HER-2 Overexpressing Locally Recurrent or Metastatic Breast Cancer
